SIRT5 and colonic neoplasm: SIRT5 demalonylates K179 of SDHA, downregulating its activity, leading to succinate accumulation and activation of the ROS scavenging enzyme thioredoxin reductase 2 (TrxR2), causing colon cancer cell resistance to rituximab [132].